Immunotherapy for colon cancer

被引：6

作者：

Bremers, AJA ^{[1
]}

Parmiani, G ^{[1
]}

机构：

[1] Ist Nazl Studio & Cura Tumori, Unit Immunotherapy, I-20133 Milan, Italy

来源：

LANCET | 1999年 / 353卷 / 9163期

关键词：

D O I：

10.1016/S0140-6736(05)75134-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1524 / 1525

页数：2

共 5 条

[1] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].

Albert, ML ;

Sauter, B ;

Bhardwaj, N .

NATURE, 1998, 392 (6671) :86-89

[2] ADJUVANT ACTIVE SPECIFIC IMMUNOTHERAPY FOR HUMAN COLORECTAL-CANCER - 6.5-YEAR MEDIAN FOLLOW-UP OF A PHASE-III PROSPECTIVELY RANDOMIZED TRIAL [J].

HOOVER, HC ;

BRANDHORST, JS ;

PETERS, LC ;

SURDYKE, MG ;

TAKESHITA, Y ;

MADARIAGA, J ;

MUENZ, LR ;

HANNA, MG .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :390-399

[3]

LABIANCA R, 1995, LANCET, V345, P939

[4]

Thurnher M, 1997, INT J CANCER, V70, P128

[5] Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial [J].

Vermorken, JB ;

Claessen, AME ;

van Tinteren, H ;

Gall, HE ;

Ezinga, R ;

Meijer, S ;

Scheper, RJ ;

Meijer, CJLM ;

Bloemena, E ;

Ransom, JH ;

Hanna, MG ;

Pinedo, HM .

LANCET, 1999, 353 (9150) :345-350

← 1 →